Abstract:Objective: To explore the value of the free triiodothyronine/thyroxine ratio (FT3/FT4), insulin-like growth factor-binding protein7 (IGFBP7), and N-terminal pro-brain natriuretic peptide (NT-proBNP) in predicting adverse outcomes of patients with acute heart failure (AHF). Methods: A total of 125 AHF patients treated at our hospital from February 2020 to February 2022 were selected. A 6-month follow-up survey was conducted, and patients were categorized into two groups based on whether adverse events such as death or recurrent heart failure occurred during the follow-up: a good prognosis group (n=44) and a poor prognosis group (n=81). General information was collected for both groups, and the FT3/FT4, IGFBP7, and NT-proBNP levels at admission were analyzed to explore their predictive value for adverse outcomes in AHF patients. Results: At admission, the FT3/FT4 levels in the poor prognosis group were lower than those in the good prognosis group, while IGFBP7 and NT-proBNP levels were higher (P<0.05). Univariate analysis revealed that age, use of β-blockers, and diuretics had an impact on patient prognosis (P<0.05). Multivariate logistic regression analysis using patient prognosis as the dependent variable (good prognosis=0, poor prognosis=1) showed that low levels of FT3/FT4 and high levels of IGFBP7 and NT-proBNP may affect adverse outcomes in patients (P<0.05). ROC curve analysis explored the predictive value of FT3/FT4, IGFBP7, and NT-proBNP levels for adverse outcomes, with AUC values of 0.899, 0.913, and 0.878, and optimal cutoff values of 69.88, 336.93, and 0.235, respectively (P<0.05). Conclusion: Serum FT3/FT4, IGFBP7, and NT-proBNP have a certain predictive value for adverse outcomes in AHF patients and can be applied in clinical practice.
雷荣浩, 肖宝珠, 潘婉, 雷杰. 血清FT3/FT4 IGFBP7与NT-proBNP预测AHF患者不良预后的价值[J]. 河北医学, 2024, 30(1): 83-88.
LEI Ronghao, XIAO Baozhu, PAN Wan, et al. The Value of Serum FT3/FT4 IGFBP7 and NT proBNP in Predicting Poor Prognosis in AHF Patients. HeBei Med, 2024, 30(1): 83-88.